SVF
Level D· Preclinical EvidenceLaboratory Study

TeSe nanoparticle-integrated exosomes for accelerated diabetic Pressure ulcer healing via NIR-II triggered synergy.

Li F., Fang Q., Zhang Y., Gong Y., Liu B.

Laboratory Study on Diabetic Foot, Chronic Wound, published in Biomater Biosyst (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Biomater Biosyst (2026)
Country
England
Reported sample size
—
PMID
42004938
DOI
10.1016/j.bbiosy.2026.100136

Abstract (original English)

Diabetic wounds, particularly combined with pressure ulcers, pose significant therapeutic challenges due to their complex pathophysiology. Conventional treatment strategies often fail to adequately address the multifactorial impairment of healing in these conditions. Here, we proposed and investigated a combinatory strategy employing human adipose-derived mesenchymal stem cell-derived exosomes (hADSC-Exos) with near-infrared-II (NIR-II)-responsive selenium telluride (TeSe) nanoparticle-mediated photothermal therapy (PTT). A full-thickness skin defect pressure ulcer model in diabetic mice was established to systematically evaluate different exosome administration regimens (single high-dose vs. multiple low-dose injections) and their combination effect with TeSe nanoparticle and NIR-II irradiation. We find that multiple low-dose subepidermal injections of hADSC-Exos resulted in more pronounced healing compared to a single high-dose strategy. The combination of low-dose exosomes with TeSe+NIR-II PTT markedly enhanced wound closure quality and stimulated hair follicle regeneration within 21 days. In vitro , TeSe nanoparticles demonstrated effective NIR-II photothermal conversion and antibacterial activity. Their integration with exosomes significantly boosted fibroblast migration and proliferation. Histological analysis confirmed that the combined therapy potently promoted angiogen

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
Hair & ScalpDiabetic FootChronic Wound
View on PubMedDOI

Related research